David D Chism
Overview
Explore the profile of David D Chism including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
1976
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Petrylak D, Eigl B, George S, Heath E, Hotte S, Chism D, et al.
Clin Cancer Res
. 2023 Oct;
30(1):63-73.
PMID: 37861407
Purpose: Effective treatment of locally advanced or metastatic urothelial carcinoma (mUC) remains an unmet need. Antibody-drug conjugates (ADC) providing targeted drug delivery have shown antitumor activity in this setting. AGS15E...
2.
Fu J, Reid S, French B, Hennessy C, Hwang C, Gatson N, et al.
JAMA Netw Open
. 2022 Mar;
5(3):e224304.
PMID: 35344045
Importance: Non-Hispanic Black individuals experience a higher burden of COVID-19 than the general population; hence, there is an urgent need to characterize the unique clinical course and outcomes of COVID-19...
3.
Hawley J, Sun T, Chism D, Duma N, Fu J, Gatson N, et al.
JAMA Netw Open
. 2022 Jan;
5(1):e2142046.
PMID: 34982158
Importance: The COVID-19 pandemic has had a distinct spatiotemporal pattern in the United States. Patients with cancer are at higher risk of severe complications from COVID-19, but it is not...
4.
Campia U, Moslehi J, Amiri-Kordestani L, Barac A, Beckman J, Chism D, et al.
Circulation
. 2019 Feb;
139(13):e579-e602.
PMID: 30786722
Cardio-oncology has organically developed as a new discipline within cardiovascular medicine as a result of the cardiac and vascular adverse sequelae of the major advances in cancer treatment. Patients with...
5.
Nakajima E, Leger P, Mayer I, Neuss M, Chism D, Rathmell W
Kidney Cancer
. 2018 Oct;
1(1):83-88.
PMID: 30334008
We report a case of severe type B lactic acidosis (LA) in a 51-year-old male, 12 days after he received his first dose of nivolumab for metastatic Von Hippel Lindau...
6.
Rose T, Chism D, Alva A, Deal A, Maygarden S, Whang Y, et al.
Br J Cancer
. 2018 Oct;
119(7):801-807.
PMID: 30293995
Background: The majority of urothelial cancers (UC) harbor alterations in retinoblastoma (Rb) pathway genes that can lead to loss of Rb tumour suppressor function. Palbociclib is an oral, selective inhibitor...
7.
Wang D, Salem J, Cohen J, Chandra S, Menzer C, Ye F, et al.
JAMA Oncol
. 2018 Sep;
4(12):1721-1728.
PMID: 30242316
Importance: Immune checkpoint inhibitors (ICIs) are now a mainstay of cancer treatment. Although rare, fulminant and fatal toxic effects may complicate these otherwise transformative therapies; characterizing these events requires integration...
8.
Choueiri T, Larkin J, Oya M, Thistlethwaite F, Martignoni M, Nathan P, et al.
Lancet Oncol
. 2018 Mar;
19(4):451-460.
PMID: 29530667
Background: The combination of an immune checkpoint inhibitor and a VEGF pathway inhibitor to treat patients with advanced renal-cell carcinoma might increase the clinical benefit of these drugs compared with...
9.
McAlister R, Aston J, Pollack M, Du L, Koyama T, Chism D
Oncologist
. 2018 Mar;
23(6):686-692.
PMID: 29487220
Background: Pazopanib is an oral tyrosine-kinase inhibitor that is approved by the U.S. Food and Drug Administration for treatment of metastatic renal cell carcinoma (mRCC). Pharmacokinetic data have shown that...
10.
Chism D
J Natl Compr Canc Netw
. 2017 Oct;
15(10):1277-1284.
PMID: 28982752
With the advent of platinum-based chemotherapy, survival rates for metastatic urothelial carcinoma have plateaued, giving way to the modern immunotherapy paradigm. Although immunotherapy as an effective treatment dates back to...